UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost
UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost
Read moreMon, 26th Oct 2020 13:37
UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost
Read moreIN BRIEF: Allergy Therapeutics Secures VLP Technology Platform
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
Read moreUK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.
Read moreIN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.
Read moreAllergy Therapeutics Anticipates Profit Ahead Of Expectations
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.
Read moreAllergy Therapeutics Well-Placed Despite Regulatory "Challenge"
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAllergy Therapeutics Outlook Confident As Revenue Rises In First Half
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.
Read moreAllergy Therapeutics Looking To Chinese Market As It Swings To Profit
Read more